BMC Cardiovascular Disorders (Sep 2010)

Efficacy of a brief multifactorial adherence-based intervention on reducing the blood pressure of patients with poor adherence: protocol for a randomized clinical trial

  • Llobera Joan,
  • Lorente Patricia,
  • Miralles Jerónima,
  • D'agosto P Pilar,
  • Serra Francisca,
  • Orueta Ramón,
  • Duro Rosa,
  • García Elena M,
  • Tamborero Gaspar,
  • González Rosa,
  • Martín Ma Carmén,
  • López Sara,
  • Audera Francisco J,
  • Escriche Luís,
  • Fajó Marta,
  • Leiva Alfonso,
  • Iglesias Ana,
  • Fernández Ruth,
  • Colom María M,
  • Buades Aina M,
  • Moreno Lucía,
  • Vidal Clara

DOI
https://doi.org/10.1186/1471-2261-10-44
Journal volume & issue
Vol. 10, no. 1
p. 44

Abstract

Read online

Abstract Background Lowering of blood pressure by antihypertensive drugs reduces the risks of cardiovascular events, stroke, and total mortality. However, poor adherence to antihypertensive medications reduces their effectiveness and increases the risk of adverse events. In terms of relative risk reduction, an improvement in medication adherence could be as effective as the development of a new drug. Methods/Design The proposed randomized controlled trial will include patients with a low adherence to medication and uncontrolled blood pressure. The intervention group will receive a multifactorial intervention during the first, third, and ninth months, to improve adherence. This intervention will include motivational interviews, pill reminders, family support, blood pressure self-recording, and simplification of the dosing regimen. Measurement The primary outcome is systolic blood pressure. The secondary outcomes are diastolic blood pressure, proportion of patients with adequately controlled blood pressure, and total cost. Discussion The trial will evaluate the impact of a multifactorial adherence intervention in routine clinical practice. Ethical approval was given by the Ethical Committee on Human Research of Balearic islands, Spain (approval number IB 969/08 PI). Trial registration Current controlled trials ISRCTN21229328